Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Trial of CTT1057 PET Imaging in Prostate Cancer
NCT02916537Phase 1Completed
- Sponsor
- Cancer Targeted Technology
- Start
- Sep 2016
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of vidoflufolastat (18F) in prostate cancer (PCa) (2 arms), sponsored by Cancer Targeted Technology. Primary endpoint: Adverse event frequency at 7 days. Started Sep 2016; status: completed.
02
Drugs
vidoflufolastat (18F)
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02916537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02916537.